Ceplene (Histamine Dihydrochloride)

What Is Ceplene and What Is It Used For?

Ceplene (histamine dihydrochloride) is an immunostimulant medication approved for remission maintenance therapy in adult patients with acute myeloid leukemia (AML) in first complete remission. It works by protecting immune cells from suppression, allowing them to more effectively eliminate residual leukemia cells when combined with interleukin-2 (IL-2).

Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow that affects the myeloid line of blood cells. While initial chemotherapy can achieve complete remission in a significant proportion of patients, relapse remains a major clinical challenge. Approximately 50-70% of adult AML patients who achieve first complete remission will eventually relapse, often within the first two years. This high relapse rate underscores the critical need for effective maintenance therapies that can sustain remission and improve long-term outcomes.

Ceplene was developed specifically to address this unmet medical need. The active substance, histamine dihydrochloride, works through a novel immunological mechanism. In the bone marrow microenvironment of AML patients, phagocytic cells such as monocytes and macrophages produce reactive oxygen species (ROS) through the enzyme NADPH oxidase. These ROS suppress the function of natural killer (NK) cells and T cells, which are the immune system's primary defense against residual leukemia cells.

By activating histamine H2 receptors on phagocytes, Ceplene inhibits NADPH oxidase activity and reduces ROS production. This effectively removes the immunosuppressive barrier, allowing NK cells and T cells to regain their cytotoxic function. When combined with IL-2, which stimulates the proliferation and activation of these effector cells, the combination therapy creates a more favorable immune environment for the eradication of minimal residual disease.

Ceplene received marketing authorization from the European Medicines Agency (EMA) in 2008 based on the results of the pivotal phase III Re:Mission trial. This randomized, controlled study demonstrated that the combination of histamine dihydrochloride and IL-2 significantly improved leukemia-free survival compared to standard of care (no treatment) in AML patients in first complete remission. The approval represented a significant advancement in post-remission therapy for patients who are not candidates for, or who have completed, allogeneic stem cell transplantation.

What Should You Know Before Taking Ceplene?

Before starting Ceplene treatment, your physician must confirm you are in first complete remission from AML. You should not use Ceplene if you are pregnant, breastfeeding, have uncontrolled cardiac conditions, or are receiving systemic corticosteroids. Blood pressure monitoring and cardiovascular assessment are essential before treatment begins.

Contraindications

Ceplene must not be used in patients with known hypersensitivity to histamine dihydrochloride or any of the excipients in the formulation. The medication is also contraindicated in patients with significant cardiac impairment, including those with New York Heart Association (NYHA) class III or IV heart failure, as histamine's vasodilatory effects can exacerbate hemodynamic instability.

Patients who have undergone allogeneic stem cell transplantation and are receiving immunosuppressive therapy, particularly systemic corticosteroids, should not use Ceplene. Corticosteroids directly antagonize the immunostimulatory mechanism of Ceplene, rendering the treatment ineffective. Additionally, patients with active, clinically significant autoimmune disease should not be treated with Ceplene, as immune stimulation could worsen autoimmune manifestations.

The medication is contraindicated during pregnancy and in women of childbearing potential not using effective contraception. Animal studies have not been conducted to fully evaluate reproductive toxicity, and the immunostimulatory effects of the treatment could theoretically harm fetal development. Breastfeeding must be discontinued during treatment, as it is unknown whether histamine dihydrochloride passes into breast milk.

Warnings and Precautions

The most clinically significant precaution relates to cardiovascular effects. Histamine is a potent vasodilator and can cause significant drops in blood pressure, particularly after injection. Patients must have their blood pressure measured before each injection, and treatment should not proceed if systolic blood pressure is below 100 mmHg. Pulse rate should also be monitored, and treatment should be withheld if the heart rate exceeds 100 beats per minute at rest.

Patients with a history of peptic ulcer disease should be monitored carefully, as histamine stimulates gastric acid secretion through H2 receptors in the stomach. Although the subcutaneous route of administration reduces direct gastric stimulation compared to systemic exposure, gastrointestinal symptoms may still occur. Patients receiving concomitant H2 receptor antagonists for peptic ulcer disease present a therapeutic conflict, as these medications directly block the receptor through which Ceplene exerts its immunomodulatory effect.

Patients with impaired renal or hepatic function should be treated with caution, as pharmacokinetic data in these populations are limited. Dose adjustments may be necessary, and more frequent monitoring of blood pressure and general clinical status is recommended. Elderly patients may be more susceptible to the hemodynamic effects of histamine and should be monitored accordingly.

Pregnancy and Breastfeeding

Ceplene is contraindicated during pregnancy. Women of childbearing potential must use effective contraception during treatment and for at least one month after the last dose. If pregnancy occurs during treatment, Ceplene and IL-2 must be discontinued immediately, and the patient should be referred for appropriate obstetric monitoring.

Breastfeeding is not recommended during Ceplene treatment. The excretion of histamine dihydrochloride in human breast milk has not been studied. Given the potential for serious adverse effects in nursing infants, including immunological effects, a decision must be made to either discontinue breastfeeding or discontinue the treatment, taking into account the benefit of treatment for the mother.

Male patients should be informed that no specific fertility data are available for Ceplene. However, the immunomodulatory nature of the treatment, combined with IL-2, warrants discussion about potential reproductive implications with the treating physician before starting therapy.

How Does Ceplene Interact with Other Drugs?

Ceplene has clinically significant interactions with H2 receptor antagonists (which block its mechanism of action), antihypertensive medications (which may worsen hypotension), systemic corticosteroids (which counteract immune stimulation), and beta-blockers. Your physician must review all medications before starting treatment.

Drug interactions with Ceplene fall into two main categories: pharmacodynamic interactions that affect its mechanism of action, and interactions that amplify or modify its side effects, particularly hemodynamic effects. Understanding these interactions is essential for safe and effective treatment.

The most important pharmacodynamic interaction involves H2 receptor antagonists such as ranitidine, famotidine, and nizatidine. Since Ceplene exerts its therapeutic effect by activating H2 receptors on phagocytic cells, concomitant use of H2 blockers directly antagonizes this mechanism and renders the treatment ineffective. These medications must be discontinued before starting Ceplene therapy. Patients requiring acid suppression should be switched to proton pump inhibitors (PPIs), which do not interfere with H2-receptor-mediated immunomodulation.

Systemic corticosteroids represent another significant contraindication for concomitant use. Corticosteroids have broad immunosuppressive effects that directly counteract the immunostimulatory goal of Ceplene plus IL-2 therapy. Patients on chronic corticosteroid therapy for conditions such as autoimmune disease or graft-versus-host disease (GVHD) are not suitable candidates for Ceplene treatment. Topical and inhaled corticosteroids at standard doses are generally acceptable, as their systemic absorption is minimal.

Antihypertensive medications, including ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, and particularly alpha-adrenergic blockers, may potentiate the hypotensive effects of histamine. Patients taking these medications require more careful blood pressure monitoring before and after each injection. Dose adjustments of antihypertensive medications may be necessary during Ceplene treatment cycles.

Major Interactions

H2 receptor antagonists and systemic corticosteroids are absolutely contraindicated with Ceplene therapy. The H2 receptor is the specific molecular target through which histamine dihydrochloride exerts its immunomodulatory effect on phagocytes. Blocking this receptor with an antagonist completely negates the therapeutic benefit. Similarly, systemic corticosteroids suppress the very immune cells (NK cells and T cells) that Ceplene and IL-2 aim to activate, creating a direct pharmacodynamic conflict.

Minor Interactions

Tricyclic antidepressants and certain first-generation antihistamines (H1 blockers) have some antihistaminic properties that could theoretically reduce Ceplene's efficacy. However, H1 receptor blockade is not the primary mechanism of Ceplene, and clinical significance of these interactions is uncertain. Patients should discuss all medications, including over-the-counter drugs and supplements, with their treating physician before starting treatment.

What Is the Correct Dosage of Ceplene?

The standard adult dose of Ceplene is 0.5 mg administered as a slow subcutaneous injection twice daily, always given 1-3 minutes after an IL-2 injection. Treatment follows a cyclical schedule: 21-day treatment periods separated by 3-week (cycles 1-3) or 6-week (cycles 4-10) rest periods, for up to 10 cycles over approximately 18 months.

Ceplene dosing follows a precisely defined cyclical schedule designed to optimize immune activation while allowing adequate recovery between treatment periods. The entire treatment program consists of up to 10 cycles administered over approximately 18 months. Each treatment day consists of two injections of Ceplene (0.5 mg each), given approximately 6-12 hours apart, always preceded by an injection of IL-2.

The injection technique is critical for both safety and efficacy. Ceplene must be injected slowly over a period of 5-15 minutes via the subcutaneous route, typically into the abdomen or thigh. Rapid injection can cause pronounced hemodynamic effects including significant hypotension, flushing, and tachycardia. The patient should be in a supine or semi-recumbent position during injection and for at least 20 minutes afterward while blood pressure is monitored.

Adults

Children

Ceplene is not approved for use in pediatric patients. The safety and efficacy of histamine dihydrochloride in combination with IL-2 have not been established in patients under 18 years of age. Pediatric AML is managed according to specific pediatric oncology protocols, which differ significantly from adult treatment strategies. No dose recommendations can be made for this population.

Elderly

No specific dose adjustment is required for elderly patients based on age alone. However, elderly patients may be more susceptible to the hemodynamic effects of histamine, including hypotension and dizziness. More careful blood pressure monitoring is recommended, and the physician should consider the patient's overall cardiovascular status, renal function, and concomitant medications when determining treatment suitability. In the pivotal clinical trial, patients up to 84 years of age were treated with Ceplene, although the majority were under 70.

Missed Dose

If a dose of Ceplene is missed, it should not be doubled up at the next administration. The missed dose should simply be skipped, and the regular dosing schedule should be resumed at the next scheduled time. If multiple consecutive doses are missed (for example, due to illness, hospitalization, or blood pressure readings below the threshold), the treating physician should be contacted to determine whether to continue the current cycle or proceed to the next rest period.

Overdose

In case of overdose, the primary clinical concern is severe hypotension and cardiovascular collapse due to histamine's vasodilatory effects. Treatment of overdose is symptomatic and supportive. Patients should be placed in the Trendelenburg position (legs elevated above the level of the heart) and receive intravenous fluids. H1 and H2 receptor antagonists may be administered to counteract the effects of excess histamine. In severe cases, vasopressors such as epinephrine or norepinephrine may be required. Continuous monitoring of blood pressure, heart rate, and oxygen saturation is essential until the patient is stabilized.

What Are the Side Effects of Ceplene?

The most common side effects of Ceplene include flushing, headache, fatigue, fever, injection site reactions, nausea, and hypotension. Most side effects are related to histamine's pharmacological action and are transient. Serious cardiovascular events are uncommon but require blood pressure monitoring before every injection.

The side effect profile of Ceplene largely reflects the pharmacological effects of histamine on the cardiovascular, gastrointestinal, and cutaneous systems. It is important to note that the side effects observed in clinical trials reflect the combination of Ceplene and IL-2, as the two medications are always administered together. Many of the reported adverse events may be attributable to IL-2 rather than Ceplene alone.

In the pivotal Re:Mission trial, the most frequently reported adverse events were related to the vasodilatory and immunostimulatory effects of the combination therapy. The majority of side effects were mild to moderate in severity (Grade 1-2) and resolved spontaneously without requiring treatment discontinuation. Severe adverse events (Grade 3-4) occurred in a minority of patients and were most commonly related to cardiovascular effects.

Patients typically experience the most pronounced side effects during the first few days of each treatment cycle, with gradual tolerance developing over the course of the 21-day treatment period. Side effects tend to be most intense immediately after injection (within the first 30-60 minutes) and diminish within a few hours. The slow injection technique (5-15 minutes) significantly reduces the severity of immediate reactions compared to rapid injection.

How Should You Store Ceplene?

Ceplene must be stored in a refrigerator at 2-8°C (36-46°F). Do not freeze. Keep the vials in the outer carton to protect from light. Once removed from the refrigerator, the solution should be allowed to reach room temperature before injection but must be used within 24 hours.

Proper storage of Ceplene is essential to maintain the stability and potency of the medication. The solution for injection contains histamine dihydrochloride in a sterile, preservative-free formulation. As a biological preparation, it is sensitive to temperature extremes and light exposure, which can degrade the active substance and reduce therapeutic efficacy.

The medication should be stored in its original packaging within a refrigerator maintained at 2-8°C (36-46°F). The outer carton provides protection from light, which is important as histamine dihydrochloride can undergo photodegradation. Vials should never be frozen, as freezing can alter the physical properties of the solution, potentially affecting the drug's bioavailability and causing crystallization of the active substance or excipients.

Before administration, the vial should be removed from the refrigerator and allowed to equilibrate to room temperature (15-25°C / 59-77°F) for approximately 15-30 minutes. Injecting cold solution can increase discomfort at the injection site. However, once removed from refrigeration, the product should be used within 24 hours and any unused portion must be discarded. Do not return a room-temperature vial to the refrigerator for later use.

Before use, visually inspect the solution for particulate matter or discoloration. The solution should be clear and colorless. Do not use if the solution appears cloudy, contains visible particles, or has changed color. Do not use after the expiration date printed on the carton and vial label. Keep all medications out of the reach and sight of children.

For patients who self-administer at home, the treating center should provide clear instructions on proper storage, including the use of a calibrated refrigerator thermometer to verify storage temperature. Patients traveling with Ceplene should use an insulated cold storage bag with appropriate cold packs, ensuring the medication does not freeze or exceed 8°C during transport.

What Does Ceplene Contain?

Each 0.5 mL vial of Ceplene contains 0.5 mg of histamine dihydrochloride as the active ingredient. The excipients include sodium chloride, sodium hydroxide (for pH adjustment), and water for injections. The solution is preservative-free and intended for single use only.

The active substance in Ceplene is histamine dihydrochloride, which is the dihydrochloride salt form of the naturally occurring biogenic amine histamine. Histamine plays multiple physiological roles in the body, including regulation of gastric acid secretion, vasodilation, immune cell modulation, and neurotransmission. In the context of Ceplene, the relevant activity is its agonist effect at H2 receptors on phagocytic cells in the immune system.

Each glass vial contains 0.5 mL of solution for injection, delivering 0.5 mg of histamine dihydrochloride (equivalent to approximately 0.28 mg of histamine base). The formulation is designed to be isotonic and physiologically compatible for subcutaneous injection. The excipients are minimal and include:

• Sodium chloride: Used to achieve isotonicity, ensuring the solution has the same osmotic pressure as body fluids, which minimizes pain and tissue irritation at the injection site
• Sodium hydroxide: Used for pH adjustment to achieve a physiologically appropriate pH that ensures both stability of the active substance and patient comfort during injection
• Water for injections: The pharmaceutical-grade solvent that forms the basis of the sterile solution

The formulation does not contain any preservatives, antimicrobial agents, or latex components. Each vial is intended for single use only, and any unused product remaining after injection must be disposed of in accordance with local requirements for pharmaceutical waste. The absence of preservatives means that the vial must not be stored after opening or used for multiple injections.

Patients with known allergies to any of the excipients should inform their physician before starting treatment. Sodium chloride is present in small quantities and is generally well-tolerated, but patients on severely sodium-restricted diets should be aware of this component.

Frequently Asked Questions About Ceplene